Together we will beat cancer

Donate

CRT’s Discovery Laboratories extends alliance with Merck to develop new cancer drugs

Cancer Research Technology has signed a further deal with Merck to discover new cancer drugs targeting the Hippo pathway.

Read More

CRT pioneer fund, Cancer Research UK and NCI collaborate to boost research against the ‘undruggable’ RAS

Cancer Research UK and the Cancer Research Technology Pioneer Fund have committed £2.5 million in collaboration with the National Cancer Institute.

Read More

Cancer Research Technology, UCL, and Tusk Therapeutics join forces to develop cancer immunotherapies

Cancer Research Technology, Tusk Therapeutics and UCL have signed an agreement to research, develop and commercialise an antibody-based therapeutic.

Read More

Cancer Research Technology and Varleigh DX (UK) Ltd launch test to support diagnosis of pancreatic cancer

Cancer Research Technology and Varleigh Dx have jointly launched a new test as an aid in the diagnosis of patients with pancreatic cancer.

Read More

Ximbio opens North America office in Cambridge, Massachusetts

Ximbio, a non-profit online one-stop-shop for the global life science community to share research resources, has opened its first North American headquarters.

Read More

Cancer Research Technology pioneer fund announces investment in blood cancer drugs

The Cancer Research Technology (CRT) Pioneer Fund announced an investment to develop a promising new class of drugs for blood cancer.

Read More

Cancer Research UK and Cancer Research Technology partner with TYG Oncology to develop next generation cancer vaccine

Cancer Research UK and Cancer Research Technology (CRT) have signed an agreement with TYG oncology Ltd (TYG) to take its new cancer vaccine into clinical trials

Read More

CRT and University of Manchester receive success payment from GlaxoSmithKline for cancer epigenetics research collaboration

Cancer Research Technology (CRT) has today received a success payment from GlaxoSmithKline resulting from its research collaboration.

Read More

Achilles Therapeutics launched with funds of £13.2 million to develop immunotherapies for cancer

Syncona LLP and Cancer Research Technology (CRT) announce the formation of Achilles Therapeutics Ltd today.

Read More

CRT and SV Life Sciences form Artios Pharma to focus on DNA damage response

Cancer Research Technology (CRT) and SV Life Sciences have today announced the launch of Artios Pharma.

Read More